Comprehensive profiling
Bring mutations and RNA findings into the same evaluation, with test options for solid tumors, blood cancers and liquid biopsy.

GOING DEEPER. SEEING MORE.
Comprehensive DNA and RNA profiling for a more complete view of cancer—and clearer direction for what comes next.
THE MOLECULAR PICTURE MATTERS
A mutation is one part of the story. Gene fusions, expression and splicing can add clinically relevant information that DNA testing alone may leave unexplored.
GTC brings these perspectives together to help clinicians interpret the disease and evaluate what comes next.
Why GTC ↗
WHY GTC
Technology matters most when it helps answer the question in front of you.
Bring mutations and RNA findings into the same evaluation, with test options for solid tumors, blood cancers and liquid biopsy.
Put molecular findings in context with expert interpretation and information relevant to treatment and diagnostic discussions.
Plan around the clinical question. Review published turnaround times and specimen requirements for the test you need.
Send testing to GTC or explore a laboratory partnership that brings genomic capabilities into your organization.
FIND THE RIGHT TEST
Explore testing by disease area and sample type. Your care team determines the appropriate test.
Compare scope, specimen requirements and turnaround times on each test page. Ready to order? ↗
CHOOSE YOUR PATH
Find the appropriate test, check specimen requirements and arrange testing.
Explore testing ↗Outsource testing or explore bringing genomic testing in-house through GTC’s cooperative model.
Explore laboratory partnerships ↗Explore sequencing, biomarker and customized assay support for research and clinical trials.
Explore research services ↗Learn about testing, find billing support and access the patient results portal.

INNOVATION IN PRACTICE / LIQUID TRACE®
Liquid Trace brings cell-free DNA and RNA profiling to blood and cerebrospinal fluid, adding molecular information to the broader clinical evaluation.
Explore distinct options for solid tumors, hematologic malignancies and cancers affecting the central nervous system.
Liquid biopsy complements other testing. A negative result does not rule out cancer.
SCIENCE & INNOVATION

FEATURED PUBLICATION / 2023
Explore GTC’s published approach to homologous recombination deficiency assessment using targeted sequencing data.
Read the study ↗GENOMIC TESTING COOPERATIVE
GTC connects genomic testing, interpretation and laboratory partnership to support the people moving cancer care forward.
Discover the cooperative model ↗NEWS & RESOURCES
